`

: Docetaxel Genmedix. ?  »
|
-

I.V

Concentrate For Solution For Infusion

Breast cancer: Docetaxel genmedix in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Docetaxel genmedix in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel genmedix monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel genmedix in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel genmedix in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Doxorubicin and cyclophosphamide followed by Docetaxel genmedix in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel genmedix in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.Non-small cell lung cancer : Docetaxel genmedix is indicated for the treatment of patients with advanced non-small cell lung carcinoma. Ovarian Cancer: Docetaxel genmedix is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. Prostate cancer: Docetaxel genmedix genmedix in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Esophageal cancer: Docetaxel genmedix for the treatment of esophageal cancer. Gastric cancer : Docetaxel genmedix for the treatment of advanced gastric cancer.Head and neck (SCCHN) :Docetaxel genmedix as monotherapy in the treatment of patients with recurrent and/or metastasic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.Docetaxel genmedix in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

146 79 33428 00

Sindan Pharma Srl, Romania

10/2011 - 09/2016

.
, .
.
/
Docetaxel 20 MG/ML
Vial glass type i 1 x 1 ML 24
Vial glass type i 1 x 4 ML 24
Vial glass type i 1 x 7 ML 24

*

*

 

.

 
" !
 
60
, -